Adjudicating the logistics of COVID-19 vaccine boosters from a global perspective글로벌 관점에서 COVID-19 백신 부스터의 물류 판단Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] booster booster vaccination booster vaccinations COVID-19 COVID-19 vaccination COVID-19 vaccine Effectiveness equity Immune escape Immune-mediated immunocompromised individuals implementation indicate Perspective Premature protective immunity protocol response SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Side effects vaccination Vaccine Vaccine hesitancy variant viral evolution waning immunity weighed [DOI] 10.1080/21645515.2021.2020572 PMC 바로가기 [Article Type] Article
Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron VariantArticle Published on 2022-12-192023-07-09 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), [키워드] booster delta variant Omicron variant SARS-CoV-2 vaccine effectiveness [DOI] 10.1093/cid/ciac328
Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021Research article Published on 2022-12-012022-10-05 Journal: Global Epidemiology [Category] 변종, [키워드] Analysis booster booster dose COVID-19 database deaths decrease delta variant Effectiveness ENhance Evolution finding France Hospitalization hospitalizations ICU admission infected individuals information National outcome performed Real-world estimates reduced remained reversed SARS-CoV-2 Spread survival symptomatic symptomatic infection symptomatic infections test-negative design vaccination Vaccine vaccine immunity variant variants waning immunity [DOI] 10.1016/j.gloepi.2022.100076 [Article Type] Research article
A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants비강 오미크론 백신 부스터는 새로운 SARS-CoV-2 변이체에 대한 강력한 중화 항체 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] absence adjuvants administration antibody Antibody Response boost booster Bronchoalveolar lavage caused clinical trial composed COVID-19 COVID-19 pandemic current deaths delta variant described disease severity domain dose effective Elevation elicit evidenced FIVE fused human infection human infections humans IgA Immunity immunogen intranasal leads mice MOST mucosal nasal nasal protein vaccine booster Neutralizing activity neutralizing antibody Neutralizing antibody response omicron Omicron variant Protein Receptor binding domain reduce respiratory SARS-CoV-2 SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 transmission SARS-CoV-2 variant severity significantly single dose suggested the antibody response the disease vaccination Vaccine virus infection wild-type [DOI] 10.1080/22221751.2022.2053365 PMC 바로가기 [Article Type] Article
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort studyArticle Published on 2022-12-012022-10-06 Journal: Lancet Reg Health Am [Category] 진단, [키워드] age All participant anti-SARS-CoV-2 BNT162b2 BNT162b2 vaccine booster Care cohort study CoronaVac COVID-19 determine dose effective end point General population groups Heterologous heterologous vaccine homologous humoral immune response IFN-γ IgG antibody IL-2 inactivated kidney liver median Medicine more difficult mRNA mRNA vaccine neutralising antibody not differ of BNT162b2 outcome Patient priming proportion Prospective prospective cohort study recipient recipients Red SARS-CoV-2 SARS-CoV-2 vaccine School secondary secreting significantly significantly higher solid organ solid organ transplant SOT T-cell T-cell responses vaccination Vaccine vaccine immunogenicity women [DOI] 10.1016/j.lana.2022.100371 PMC 바로가기 [Article Type] Article
Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in KoreaArticle Published on 2022-12-012023-07-10 Journal: Journal of microbiology, immunology, and infection [Category] COVID19(2023년), [키워드] booster COVID-19 Interferon-gamma (IFN-γ) neutralizing antibody Vaccine [DOI] 10.1016/j.jmii.2022.09.004 PMC 바로가기
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé omicron Omicron variant overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
The impact of maternal SARS-CoV-2 infection and COVID-19 vaccination on maternal-fetal outcomesReview Published on 2022-12-012023-07-10 Journal: Reproductive toxicology (Elmsford, N.Y.) [Category] COVID19(2023년), [키워드] booster COVID-19 Pregnancy Preterm birth SARS-CoV-2 Stillbirth vaccination Vaccination hesitancy [DOI] 10.1016/j.reprotox.2022.10.003 PMC 바로가기 [Article Type] Review